Creo Medical Group PLC (AIM:CREO) said trading so far this year has been strong, continuing the momentum seen in 2021.
“The solid progress made over the past year reinforces the board’s continued confidence in the group’s opportunities in 2022 and beyond,” Chairman Charles Spicer said in a statement released ahead of the AGM. ‘today.
The medical device company focused on surgical endoscopy saw its total sales in 2021 rise to £25.2m from £9.4m the previous year.
READ: Creo Medical signs collaboration with NASDAQ-listed medical technology Intuitive
Spicer said the commercialization of the company’s endoscopy devices continues apace.
“We anticipate that high vaccination rates in Europe and the United States will continue to mitigate the impact of COVID-19 through the remainder of 2022, allowing clinicians to focus on the huge backlog of elective cases, increasing the activity in our main areas of clinical interest. – Removal of the gastrointestinal nucleus and soft tissues,” he added.
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that nothing posted on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction or investment strategy is…
In exchange for publishing services rendered by Company on behalf of Creo Medical Group PLC named herein, including Company’s promotion of Creo Medical Group PLC in any Site Content, Company…
FOR OUR FULL DISCLAIMER, CLICK HERE